Edition:
United Kingdom

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

22.41USD
21 Aug 2018
Change (% chg)

$0.57 (+2.61%)
Prev Close
$21.84
Open
$22.00
Day's High
$22.50
Day's Low
$21.87
Volume
167,935
Avg. Vol
192,562
52-wk High
$43.98
52-wk Low
$13.85

Latest Key Developments (Source: Significant Developments)

Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia
Thursday, 15 Mar 2018 

March 15 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS PHARMACEUTICALS INC -.ADAMAS ANNOUNCES PUBLICATION OF DATA SUPPORTING THE BENEFITS OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA.ADAMAS PHARMACEUTICALS - ANNOUNCES RESULTS FROM TWO POOLED PHASE 3 STUDIES IN PARKINSON'S DISEASE PATIENTS WITH DYSKINESIA.ADAMAS PHARMACEUTICALS - THE 2 POOLED PHASE 3 STUDIES SHOWED GOCOVRI-TREATED PATIENTS EXPERIENCED 41 PERCENT FALL IN DYSKINESIA FROM BASELINE AT WEEK 12.  Full Article

Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers
Monday, 12 Mar 2018 

March 12 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS PHARMACEUTICALS SAYS ‍AS OF FEB 28, CO RECEIVED PRESCRIPTIONS FOR GOCOVRI FROM ABOUT 390 DISTINCT PRESCRIBERS - SEC FILING​.ADAMAS PHARMACEUTICALS INC - ‍FILLED GOCOVRI PRESCRIPTIONS FOR PERIOD FROM JAN 1, 2018, THROUGH FEB 28, 2018, WERE 742​.  Full Article

Adamas Q4 Loss Per Share $1.27
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017.Q4 LOSS PER SHARE $1.27.SAYS FOR 2018, ADAMAS EXPECTS FULL-YEAR RESEARCH AND DEVELOPMENT EXPENSES TO BE BETWEEN $45 MILLION AND $50 MILLION.QUARTERLY TOTAL NET REVENUES $568,000 VERSUS $37,000.  Full Article

Adamas prices offering Of 3 mln shares at $41.50 per share
Wednesday, 24 Jan 2018 

Jan 23 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.ADAMAS PHARMACEUTICALS INC - ‍PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $41.50 PER SHARE​.  Full Article

Adamas Pharmaceuticals reports Q3 loss per share $1.04
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results.Q3 loss per share $1.04.Q3 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.Adamas Pharmaceuticals Inc - ‍ expects to receive $65 million in funding from healthcare royalty partners in q4 of 2017.Adamas Pharmaceuticals Inc - ‍ believe we will be sufficiently capitalized to launch and commercialize gocovri, among others​.  Full Article

Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Adamas Pharmaceuticals Inc :Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​.  Full Article

Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Adamas Pharmaceuticals Inc :Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​.  Full Article

Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Adamas Pharmaceuticals Inc ::FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI.  Full Article

Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals‍​
Thursday, 7 Sep 2017 

Sept 8 (Reuters) - Adamas Pharmaceuticals Inc :Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals as of August 29 - SEC filing .‍​.  Full Article

Adamas announces FDA approval of Gocovri as first and only medication for dyskinesia treatment in Parkinson’s disease patients
Thursday, 24 Aug 2017 

Aug 24 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals Inc - ‍Gocovri is expected to be available in Q4, and formally launched in Jan 2018​.  Full Article

BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri

* ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA